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Monitoring plasma levels of ganciclovir in AIDS patients receiving oral
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Objective To investigate whether low ganciclovir serum levels in patients on maintenance oral ganciclovir
therapy are associated with recurrence of CMV retinitis.
Methods A prospective study of the plasma concentration of ganciclovir after initiation of maintenance oral
ganciclovir therapy in 14 AIDS patients who had recovered from acute cytomegalovirus (CMV) retinitis.
Results Five of the 14 patients exhibited a mean time to recurrence of 37 days. The mean trough plasma
concentration of ganciclovir in these patients after 1 month of oral ganciclovir therapy, was 0.402 0.30mg/L.
Nine patients had a mean time of progression of 263 days. The mean trough plasma concentration of ganciclovir
in the latter patients was 0.802 0.60mg/L.
Conclusions Patients exhibiting trough plasma levels of ganciclovir below 0.6mg/L may be at higher risk of
progression than patients who exhibited levels above 0.6mg/L.
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INTRODUCTION
Retinitis is the major manifestation of acute cytomegalovirus
(CMV) disease in AIDS [1,2]. Although the prevalence of CMV
infections in patients with advanced HIV disease has decreased
with recent advances in antiretroviral therapy, CMV retinitis
remains associated with substantial morbidity, mortality and
impaired quality of life.
Intravenously administered ganciclovir has been proved to
be beneﬁcial in AIDS patients with CMV retinitis, both as
induction therapy and maintenance treatment of CMV retinitis
[3]. Oral ganciclovir at 3000mg/day has also been shown to be
effective in preventing the recurrence of CMV retinitis in AIDS
[4,5], and one study has suggested that oral ganciclovir may be
effective as primary prophylaxis of acute CMV disease in pat-
ients with AIDS [6]. However, CMV retinitis usually recurs
within 862 5 days despite maintenance therapy [5].
The response to treatment with ganciclovir is inﬂuenced
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by pharmacokinetic variability between subjects. Thus, during
induction treatment, low plasma concentrations of ganciclovir
have been shown to be associated with failure of therapy [7].
Oral ganciclovir has a low bioavailability ranging between 3
and 9%. With intakes of 1000mg every 8 h, the mean trough
levels of ganciclovir in serum have been reported to be between
0.3 and 0.5mg/L [8,9]. The present study was designed to
investigate whether trough plasma levels of ganciclovir may be
of value in monitoring AIDS patients on maintenance therapy
with this drug.
PATIENTS AND METHODS
Study population
Plasma levels of ganciclovir were measured prospectively in 14
randomly selected patients with AIDS from January 1995 to
October 1996. All patients had had acute CMV retinitis without
evidence of other end-organ disease and had been treated with
intravenous ganciclovir, 5mg/kg twice daily for 21 days, before
being started on maintenance oral ganciclovir at 1000mg every
8 h. Oral ganciclovir was supplied in 250mg hard gelatin
capsules. All patients had normal renal function. The patients
were evaluated weekly by fundus examination during induction
therapy and then twice a month by the same ophthalmologist.
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Failure of treatment was deﬁned as the progression of the limits
of the initial lesion or the appearance of a new lesion in a
previously uninvolved area. All the patients were maintained on
antiretroviral therapy during the study. During oral ganciclovir
maintenance therapy, a protease inhibitor was added to current
antiretroviral treatment for ﬁve out of the 14 patients.
Sample collection and analytical method
Blood samples were drawn at steady-state just before intake of
the drug (trough level) once during the ﬁrst month after
initiation of maintenance treatment. Considering the short
elimination half-life of oral ganciclovir of 4.4 h [10], this steady
state was achieved in all patients after 1 day of therapy. In six
patients, several samples were available after the ﬁrst month of
therapy and did not exhibit a signiﬁcant variability. All samples
were processed using an original method combining ion-pair
high performance liquid chromatography (HPLC) and spectro-
photometric UV detection at 254 nm [11]. Five hundred
microlitres of plasma were deproteinized using 6% perchloric
acid, and aciclovir (2.5 mg) was added as an internal standard.
Samples were mixed, centrifuged, and the supernatant neu-
tralized with 22% sodium acetate. Aliquots of 50mL were then
injected onto a 15-cm× 4.6mm (internal diameter) Lich-
rospher 100 C-18 column (Merck, Darmstadt, Germany). The
column was eluted at a constant ﬂow rate of 1mL/min with
0.005M sodium 1-heptane sulphonate and 0.02M potassium
dihydrogen phosphate adjusted to pH2.6with phosphoric acid-
acetonitrile (98 : 1, v/v). The threshold of sensitivity of the assay
was 0.1mg/L ganciclovir.
Statistical analysis
Time to recurrence of retinitis was measured from the date of
initiation of maintenance therapy. We ﬁrst compared mean
trough levels of patients with a short interval before recurrence
(less than 90 days) and with those with an interval to recurrence
over 90 days. The period of 90 days was selected because it
corresponds to the mean time to progression with oral main-
tenance ganciclovir as reported previously by the European and
Australian cooperative study group [5]. Statistical analysis was
carried out using Student’s t-test.
We then assessed the time to progression in relation to trough
levels of ganciclovir by separating the patients on the basis of
trough plasma concentrations of ganciclovir below or over
0.6mg/L, using Kaplan–Meier plots and log-rank tests. This
cut-off was chosen since residual plasma concentrations above
0.6mg/L have been found to correlate with successful treat-
ment of acute CMV infection with intravenously administered
ganciclovir [7,12,13]. If a patient did not progress within the
period of the study, time to progression was taken as the date
of the last ophtalmologic examination before study termination.
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RESULTS
The patients were 13 males and one female aged between 30
and 51 (mean age 392 6 years). The mean CD4 cell count at
diagnosis of CMV retinitis and at the end of follow-up on
ganciclovir oral therapy were 142 10× 106/L (ranging
between 1 and 60) and 292 42 (1–158), respectively. The
mean plasma HIV-RNA levels at diagnosis of CMV retinitis
and at the end of follow-up on ganciclovir oral therapy were
5.22 0.4 Log/mL (ranging between 4.6 and 5.6) and
3.52 0.92 (2.7–5.15), respectively.
The mean trough plasma concentrations of ganciclovir were
0.632 0.54mg/L, ranging between 0.15 and 1.90mg/L (Fig-
ure 1). The mean time of progression was 1722 124 days with
a median of 115 days, ranging between 23 and 441 days.
In ﬁve of the 14 patients the time to recurrence was less than
90 days. The mean time to progression was 372 9 days and
the mean trough plasma concentration of ganciclovir in these
patients was 0.402 0.30mg/L. Two of these ﬁve patients were
receiving combined antiretroviral therapy including a protease
inhibitor. In the other nine patients their time period to recur-
rence was longer (over 90 days). Their mean time to progression
was 2632 102 days (ranging between 110 and 441 days) and
the mean trough plasma concentration of ganciclovir was
0.802 0.60mg/L. Three of these nine patients were receiving
a protease inhibitor. Thus, low trough plasma concentrations
were associated with earlier recurrence of retinitis, although the
difference did not reach statistical signiﬁcance.
Nine patients had plasma trough levels of ganciclovir below
0.6mg/L and ﬁve had levels above 0.6mg/L. The risk of
progression was higher in the group of patients with low
residual concentrations of the drug, although, as above, no
signiﬁcant statistical difference was reached (Figure 2).
Figure 1 Distribution of trough ganciclovir plasma levels at steady
state in 14 patients treated with oral ganciclovir 1000mg three times
daily.
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Figure 2 Proportion of patients remaining free of progression on
maintenance therapy with oral ganciclovir as determined by fun-
doscopy assessments (Kaplan–Meier estimates). () Patients exhi-
biting trough plasma levels of ganciclovir ³0.6mg/L (n=9); ()
patients exhibiting trough plasma levels of ganciclovir −0.6mg/L
(n=5); P=0.58 using a log-rank comparison test.
DISCUSSION
Few pharmacokinetic studies are available for oral ganciclovir.
Low bioavailability of oral ganciclovir is a limitation on treat-
ment of CMV infection [8–10]. Differences in ganciclovir phar-
macokinetics have been observed between different popula-
tions of patients [14]. Ganciclovir is metabolized intracellularly
into an active triphosphated form by kinases and the intracellular
levels of the active ganciclovir triphosphate are the real deter-
minant of drug efﬁcacy. Nevertheless, serum levels of the pro-
drug may serve as a surrogate marker for intracellular levels of
ganciclovir [7,12].
Two previous studies have reported mean trough plasma
levels of 0.542 0.32 and 0.232 0.07mg/L, and mean peak
plasma levels of 1.112 0.56mg/L and 1.182 0.36mg/L after
an oral regimen of 1000mg every 8 h in HIV-infected patients
[8,9]. The mean plasma ganciclovir concentrations were thus
within the range known to inhibit 50% of most clinical CMV
isolates [15–18]. In the present study, we observed mean trough
levels of 0.632 0.54mg/L in 14 patients, with low intersubject
variability. There was no statistically signiﬁcant relationship
between trough levels of ganciclovir and time to progression
of CMV retinitis, whichmay be dependent on the small number
of patients in the study since there was a clear trend towards
more rapid progression in patients exhibiting lower trough
levels of the drug. In addition, we had previously shown that
plasma concentrations of ganciclovir below 0.6mg/L were
associated with failure of therapy during induction treatment
of CMV retinitis with intravenously administered ganciclovir
[7]. A plasma ganciclovir concentration of 1.0mg/L is associ-
ated with efﬁcacy of oral ganciclovir for prophylaxis against
CMV after renal transplantation [19]. In the present study, we
have not measured resistance to ganciclovir that could over-
ride the signiﬁcance of blood levels of ganciclovir. However,
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viral resistance has been observed with a frequency of 6.5%,
in patients having received a prolonged treatment with oral
ganciclovir [20].
We suggest that studies designed for predicting the outcome
of ganciclovir therapy in CMV retinitis should use both viro-
logical markers such as plasma levels of viral DNA and
pharmacokinetic parameters, in order to optimize the care of
patients.
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